1617532-01-0

Basic information

• Product Name: 3-(1-p-toluenesulfonyl-1H-benzo[d]imidazol-2-yl)propan-1-ol
• Synonyms: 3-(1-p-toluenesulfonyl-1H-benzo[d]imidazol-2-yl)propan-1-ol
• CAS NO: 1617532-01-0
• Molecular Weight: 330.408
• Mol File: 1617532-01-0.mol

Chemical Properties

• CAS DataBase Reference: 3-(1-p-toluenesulfonyl-1H-benzo[d]imidazol-2-yl)propan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1-p-toluenesulfonyl-1H-benzo[d]imidazol-2-yl)propan-1-ol(1617532-01-0)
• EPA Substance Registry System: 3-(1-p-toluenesulfonyl-1H-benzo[d]imidazol-2-yl)propan-1-ol(1617532-01-0)

Safety Data

• Hazardous Substances Data: 1617532-01-0(Hazardous Substances Data)

Upstream product

• 2403-66-9 2-(3-hydroxypropyl)benzimidazole 
• 104-15-4 toluene-4-sulfonic acid 

Downstream Products

• 1617531-85-7 3-(1-p-toluenesulfonyl-1H-benzo[d]imidazol-2-yl)propanal 

Relevant articles and documents

Efficient synthesis of mibefradil analogues: An insight into in vitro stability

This article describes the synthesis and biological evaluation of a chemical library of mibefradil analogues to investigate the effect of structural modification on in vitro stability. The construction of the dihydrobenzopyran structure in mibefradil derivatives 2 was achieved through two efficient approaches based on a diastereoselective intermolecular Reformatsky reaction and an intramolecular carbonyl-ene cyclization. In particular, the second strategy through the intramolecular carbonyl-ene reaction led to the formation of a key intermediate 3 in a short and highly stereoselective way, which has allowed for practical and convenient preparation of analogues 2. Using this protocol, we could obtain 22 new mibefradil analogues 2, which were biologically tested for in vitro efficacies against T-type calcium channels and metabolic stabilities. Among the synthesized compounds, we found that analogue 2aa containing a dihydrobenzopyran ring and a secondary amine linker showed high % remaining activities of the tested CYP enzymes retaining the excellent T-type calcium channel blocking activity. These findings indicated that the structural modification of 1 was effective for improving in vitro stability, i.e., reducing CYP inhibition and metabolic degradation. the Partner Organisations 2014.

4-Isopropylchroman-3-ol derivatives

The present invention relates to a novel 4-isopropylchroman-3-ol compound, a pharmaceutical composition comprising the novel compound as an effective component, and to an intermediate compound useful for synthesizing the compound. When administered to a patient with a drug causing toxicity, the novel 4-isopropylchroman-3-ol compound exhibits efficacy of reducing toxicity of the drug by reducing antagonism regarding a T-type calcium channel and/or activity of cytochrome P450 isozyme.